GO
Loading...

GlaxoSmithKline PLC

More

  • Stocks Rise as Oil Drops More Than $1 Wednesday, 23 Jul 2008 | 11:44 AM ET

    Stocks advanced, boosted by a further drop in oil following the inventory report and expectations that the House would pass the Fannie Mae-Freddie Mac rescue plan.

  • Glaxo Earnings Rise 13%, Cautious on Outlook Wednesday, 23 Jul 2008 | 8:19 AM ET

    GlaxoSmithKline's new chief executive set out plans to make the world's second largest drug maker a broader business with lower costs, but kept a cautious view on short-term prospects that knocked its shares.   

  • Big Pharma Is Scrambling To Buy More Biotech Firms Monday, 21 Jul 2008 | 11:11 AM ET

    Roche Holdings' $43.7 billion bid to buy the rest of Genentech highlights drugmakers' growing reliance on biotech products.

  • Roche Offers to Buy Out Genentech for $43.7 Billion Monday, 21 Jul 2008 | 6:33 AM ET

    Swiss drugmaker Roche Holding offered to acquire all outstanding shares in its U.S. partner Genentech for $43.7 billion in cash to reinforce its position in cancer medicines.

  • Lilly's Sex Survey: Will It Have Desired Effect On Cialis? Wednesday, 16 Jul 2008 | 12:31 PM ET
    Lilly

    More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.

  • UBS And Its Guarded Outlook For Merck's Gardasil Monday, 7 Jul 2008 | 11:14 AM ET

    Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...

  • Biopharma Analyst Musical Chairs Wednesday, 2 Jul 2008 | 11:16 AM ET

    In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.

  • Dealing With a Decimated Dow Thursday, 26 Jun 2008 | 6:30 PM ET

    Cramer offers his plan of action to handle a 358-point decline.

  • Dow Falls Below 12,000 Friday, 20 Jun 2008 | 5:53 PM ET

    The Dow closed sharply lower Friday, registering its third triple-digit loss in four sessions. What's the "Word on the Street?"

  • My ASCO Fiasco Tuesday, 3 Jun 2008 | 8:58 AM ET

    This year, for the first time ever, ASCO agreed to let CNBC broadcast live from inside McCormick Place. It took years of reasoning, pleading, nagging and complaining to get inside. But finally, ASCO consented. In the past, the scientific organization has tried to keep more than an arm's distance from the financial media.

  • Inflation, Credit Worries Dent Europe Stocks Tuesday, 27 May 2008 | 1:01 PM ET

    A bout of risk aversion dented European stocks on Tuesday as jitters grew over potential credit-related problems at banks and inflation, while typically defensive stocks such as pharmaceuticals and food rallied.

  • Are Impotence Drugs Good for Your Heart? Monday, 19 May 2008 | 5:43 PM ET

    A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.

  • Pfizer And Amgen Trade "Political" Places Monday, 19 May 2008 | 10:51 AM ET
    Amgen

    Up until last month, AMGN had been atop the list of pharmaceutical manufacturer donors and PFE was in a close second. But the CRP says they flip-flopped in the most recent month that figures are available. So far, in the 2008 election cycle, Pfizer's given $862,000 to candidates and Amgen has forked over $852,000.

  • Biotech's Big Night Thursday, 15 May 2008 | 6:38 PM ET

    Traders will be glued to the web Thursday night as thousands of cancer studies go online. What’s the trade as these studies potentially send shock waves through biotech stocks on Friday morning?

  • Palatin Technologies: No Nose For Impotence Wednesday, 14 May 2008 | 11:45 AM ET
    Palatin Technologies

    I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.

  • Lightning Round: Apple, Conoco, JPMorgan and More Friday, 25 Apr 2008 | 7:17 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Amgen: Is "A" For Anemia Or Acquisition? Friday, 25 Apr 2008 | 12:35 PM ET
    AMGEN

    The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.

  • Thusday Look Ahead: Earnings to Set Course Wednesday, 23 Apr 2008 | 6:05 PM ET

    Some late day earnings news could spill into Thursday's session: Apple shares rose after the company reported a 36 percent increase in profits to $1.05 billion. But the company guided third quarter below Wall Street estimates...

  • Glaxo Buying Sirtris -- A Euro/Dollar Story Wednesday, 23 Apr 2008 | 3:34 PM ET

    GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. This price represents an 84% premium over SIRT's closing price yesterday. Two things are going on here...

  • Schering Plows Through Vytorin Firestorm Wednesday, 23 Apr 2008 | 12:57 PM ET

    Schering-Plough beat the Street by a surprising 16 cents per share and the beaten-down shares are rallying. In an exclusive CNBC interview Wednesday morning, Chairman and CEO Fred Hassan explained how the company was able to blow away estimates...